AWM Investment Company Inc. purchased a new position in SAB Biotherapeutics, Inc. (NASDAQ:SABS - Free Report) during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 375,000 shares of the company's stock, valued at approximately $1,462,000. AWM Investment Company Inc. owned 0.41% of SAB Biotherapeutics as of its most recent filing with the Securities and Exchange Commission (SEC).
Several other hedge funds also recently bought and sold shares of SABS. Vivo Capital LLC purchased a new stake in shares of SAB Biotherapeutics during the 3rd quarter worth $22,954,000. Perceptive Advisors LLC grew its stake in SAB Biotherapeutics by 700.8% in the first quarter. Perceptive Advisors LLC now owns 6,431,743 shares of the company's stock valued at $24,634,000 after purchasing an additional 5,628,533 shares during the last quarter. RA Capital Management L.P. purchased a new position in SAB Biotherapeutics in the third quarter valued at about $8,847,000. Woodline Partners LP bought a new position in SAB Biotherapeutics in the third quarter worth about $5,730,000. Finally, Spruce Street Capital LP purchased a new stake in shares of SAB Biotherapeutics during the fourth quarter valued at about $8,222,000. Institutional investors own 7.82% of the company's stock.
Analyst Upgrades and Downgrades
Several research firms recently commented on SABS. HC Wainwright restated a "buy" rating and set a $10.00 price target on shares of SAB Biotherapeutics in a research report on Monday, June 15th. Rodman & Renshaw restated a "buy" rating and set a $13.00 target price on shares of SAB Biotherapeutics in a research report on Monday, May 11th. Leerink Partners lifted their price target on SAB Biotherapeutics from $7.00 to $12.00 and gave the company an "outperform" rating in a research note on Monday, June 15th. Barclays assumed coverage on SAB Biotherapeutics in a report on Wednesday, June 24th. They issued an "overweight" rating and a $13.00 price target for the company. Finally, Wall Street Zen upgraded SAB Biotherapeutics from a "strong sell" rating to a "sell" rating in a research report on Monday, August 10th. Nine research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company's stock. According to MarketBeat.com, SAB Biotherapeutics has a consensus rating of "Moderate Buy" and an average price target of $12.00.
Check Out Our Latest Research Report on SAB Biotherapeutics
SAB Biotherapeutics Stock Performance
Shares of SAB Biotherapeutics stock opened at $3.81 on Wednesday. The business has a 50-day moving average of $3.75 and a 200 day moving average of $3.79. SAB Biotherapeutics, Inc. has a 12 month low of $1.85 and a 12 month high of $5.15. The stock has a market capitalization of $346.67 million, a price-to-earnings ratio of -2.93 and a beta of 0.53. The company has a debt-to-equity ratio of 0.01, a current ratio of 9.22 and a quick ratio of 9.22.
SAB Biotherapeutics (NASDAQ:SABS - Get Free Report) last announced its quarterly earnings data on Thursday, August 6th. The company reported ($0.28) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.28). As a group, sell-side analysts forecast that SAB Biotherapeutics, Inc. will post -1.17 earnings per share for the current year.
About SAB Biotherapeutics
(
Free Report)
SAB Biotherapeutics, Inc is a clinical-stage biotechnology company headquartered in Sioux Falls, South Dakota, that focuses on developing fully human polyclonal antibody therapeutics. The company's proprietary platform, known as Tc Bovine®, uses genetically engineered cattle to generate large quantities of human antibodies tailored to target specific infectious agents or disease-related antigens. This approach is designed to combine the broad-spectrum coverage of polyclonal antibody therapies with the scalability and consistency required for clinical development and commercial use.
The company's lead programs are directed primarily at infectious diseases.
Further Reading
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Before you consider SAB Biotherapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and SAB Biotherapeutics wasn't on the list.
While SAB Biotherapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation.
Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
